Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.

ABSTRACT:

SUBMITTER: Ferrara R 

PROVIDER: S-EPMC8092423 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature